Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

28,775 28,651 28,734 28,637

(1) Includes $- and $77 as additional research and development expense,

which represents an estimate of the net payable due to Novartis of

ANA975 research and development costs for the three months ended

September 30, 2008 and 2007, respectively. Includes ($47) and ($514)

as an offset in research and development expense, which represents an

estimate of the net reimbursement by Novartis of ANA975 research and

development costs for the nine months ended September 30, 2008 and

2007, respectively.

(2) Includes non-cash operating expenses of $738 and $1,392 determined in

accordance with Statement of Financial Accounts Standards No. 123(R),

"Share-Based Payment" (SFAS No. 123(R)) or approximately $0.03 and

$0.05 effect on basic and diluted net (loss) income per common share

for the three months ended September 30, 2008 and 2007, respectively.

Research and development expense and general and administrative

expense includes $326 and $412 of non-cash operating expenses

determined in accordance with SFAS No. 123(R) for the three months

ended September 30, 2008. Includes non-cash operating expenses of

$2,065 and $3,502 determined in accordance with SFAS No. 123(R) or

approximately $0.07 and $0.12 effect on basic and diluted net loss per

common share for the nine months ended September 30, 2008 and 2007,

respectively. Research and development expense and general and

administrative expense includes $949 and $1,116 of non-cash operating

expenses determined in accordance with SFAS No. 123(R) for the nine

months ended September 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)


'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Research and Markets has ... Diagnostics Market (Product types, Application, Technology, End User ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... their offering. This new report ... users and Geography) Global Size, Industry Analysis, Trends, ...
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
Breaking Biology Technology:Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... June 29 The California Department of Labor today ... million grant to implement new workforce training programs for ... Initiative, a collaborative effort including CleanTECH San Diego, BIOCOM, San ... and the San Diego Workforce Partnership, captured the grant through ...
... SAN DIEGO , June 29 ... key commercialization milestones ahead of schedule. First, the company ... and commercial viability of a ,green, version of 1,4-butanediol ... confirmed the accelerated development time and reduced development and ...
... June 29, 2010 , , , ... it Will Carry the Disease and Therapy,Review: Impetigo Market Research Report in its Store. ... Browse the complete Report on:, http://www.reportsandreports.com/market-reports/disease-and-therapy-review-im ,petigo/ , ... The Impetigo Disease and Therapy Review provides an overview ...
Cached Biology Technology:San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 2San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 3San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry 4Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 2Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 3Genomatica Delivers Pilot-Scale Validation in Sustainable Chemical Manufacturing 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 2Disease and Therapy Review: Impetigo Now Available at ReportsandReports 3Disease and Therapy Review: Impetigo Now Available at ReportsandReports 4Disease and Therapy Review: Impetigo Now Available at ReportsandReports 5
(Date:10/25/2014)... --  MedNet Solutions , a global life sciences technology ... to announce the 2014 iMedNet User Group ... in Bloomington, Minnesota on October ... and promises to be informative, productive and enjoyable for ... meeting is iMedNet™ EDC , MedNet,s ...
(Date:10/25/2014)... This report covers the specifics of microRNA ... heavy pursuit of research due to its versatility and ... other RNA components. miRNA,s non-coding nature and ability to ... use as a biomarker for a variety of diseases. ... for the advancement in therapeutic development. Furthermore there are ...
(Date:10/25/2014)... -- A recent report, "Genetic Testing Market Outlook 2018", ... genetic testing market. A comprehensive introduction of gene-based tests, ... report. On account of our analysis of the past ... challenges; forecast for genetic testing has been drawn, according ... a CAGR of around 9% during 2013-2018. Our ...
Breaking Biology News(10 mins):MedNet Solutions To Host Third Annual iMedNet User Group Meeting 2MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors 2Genetic Testing Market Outlook 2018 2
... Scientists at St. Jude Children's Research Hospital have announced ... against one antigenic variant of the avian influenza virus ... virus. Vaccines based on this model might therefore be ... epidemic) until a new vaccine could be developed specifically ...
... half of human cancers involve mutations in the p53 ... normal p53 protein in defending against cancer. Similarly, roughly ... occur in its DNA-binding core domain, pointing to this ... its anti-cancer activity. , Clearly, a detailed view of ...
... a lifetime of daily injections to replace the ... as a host of risks that includes blindness, ... particularly those afflicted with juvenile diabetes, transplants of ... might alleviate these problems. Unfortunately, there are not ...
Cached Biology News:Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity 2Successful transplantation from pig embryos to mice 2
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... raised against a partial recombinant ... PPP4C (NP_002711, 218 a.a. ... protein with GST tag. ... NM_002720 Protein ...
... Eppendorf Thermomixer R offers maximum application ... shaking, heating, and cooling. Its active ... application and temperature control ranges. Five ... 24 micro test tubes, are available ...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
Biology Products: